Biochimica/Lilly Ceclor
Executive Summary
Aventis subsidiary Biochimica will pay Lilly $110 mil. for the settlement of all litigation regarding the antibiotic cefaclor. Lilly initiated a patent lawsuit in 1995 and a civil suit in 1997. Lilly's litigation against Ivax/Zenith is still ongoing